Zopiclon

Description

Zopiclone (Imovane, Zimovane, Ximovan) is the first cyclopyrrolone and belongs to the so-called Z-drugs - non-benzodiazepine hypnotics that are chemically unrelated to benzodiazepines but hit the same target. Zopiclone acts as a positive allosteric modulator at the GABA-A receptor: it binds at the benzodiazepine binding site of the receptor complex and amplifies the inhibitory action of the body’s own GABA. The result is broad dampening of neuronal activity with a pronounced sedative emphasis.

Unlike zolpidem, which binds preferentially to alpha-1 containing receptor subtypes, zopiclone is non-selective across subtypes. That explains the effect profile: alongside sedation, anxiolytic, muscle-relaxant and anticonvulsant components are documented in studies - and with them a side effect and dependence profile that sits considerably closer to the benzodiazepines than the label “non-benzodiazepine” suggests.

Pharmacokinetically, zopiclone is rapidly absorbed orally with a bioavailability of roughly 75-80 percent. Peak plasma levels are reached after about 1.5 to 2 hours and onset typically occurs within 30 minutes. Elimination half-life is around 5 hours in healthy adults and rises to 7 hours or more in older individuals and in impaired liver function. Metabolism runs via CYP3A4 and CYP2C8, so inhibitors of these enzymes (ketoconazole, erythromycin, ritonavir) raise both levels and sedation. Eszopiclone is the S-enantiomer of the same molecule.

The efficacy data are solid: zopiclone 7.5mg shortens sleep latency and extends total sleep time at least as well as classic benzodiazepine hypnotics. The safety data are the actual point. Older reviews from the 1990s described the dependence risk as low - newer data contradict that clearly. In a national French survey of more than 1000 people aged 65 and over who had used benzodiazepines or Z-drugs for at least three months, 45 percent met the formal DSM criteria for dependence. Tolerance to the sleep-inducing effect is documented within 2 to 4 weeks, as is rebound insomnia after discontinuation. That is exactly why international guidelines cap use at 2 to 4 weeks including tapering - that is not a cautious suggestion, it is the ceiling.

Two further findings belong here without exception. First: in a meta-analysis of standardized on-the-road driving tests, zopiclone 7.5mg clearly impaired driving performance the morning after evening dosing. The effect was even more pronounced after middle-of-the-night dosing. Zolpidem and zaleplon did not show this morning effect in the same analyses. Second: complex sleep behaviors - sleepwalking, cooking, phoning and driving while asleep with no recollection afterward - led the FDA to issue a Boxed Warning for the entire Z-drug class in 2019. The underlying review of the FDA adverse event database covered 66 cases with serious injuries, including 20 deaths. These events also occurred on first use and at normal doses. Combining zopiclone with alcohol, opioids or other respiratory depressants is potentially fatal - that is not a residual risk, it is the primary mechanism by which Z-drugs appear in mortality statistics.

You can order zopiclone as oral tablets, with 7.5mg per tablet as a blister of 10 or a bottle of 100 and with 10mg as a blister of 10 or 14 tablets. The 100-tablet bottle exceeds the use duration foreseen in guidelines by a large multiple - it is a stock quantity, not a usage instruction.

This information is for research and educational purposes only. No medical advice.

Risks & Safety

Zopiclone has the highest dependence potential in the entire TPD catalog. That is not a hedge and not a formality: the substance produces tolerance, physical dependence and withdrawal in a clinically documented way. It does so at normal doses and within a few weeks. Anyone touching zopiclone should know the full risk profile before the first tablet is opened.

Documented in clinical studies and pharmacovigilance data:

• Dependence: in a national survey, 45 percent of people who had used benzodiazepines or Z-drugs for at least three months met the formal DSM dependence criteria. That is the highest documented dependence rate of any substance in this catalog. Pre-existing addiction disorders or psychiatric diagnoses raise the risk further and substantially.
• Tolerance within 2-4 weeks: the sleep-inducing effect wanes under daily use. The typical documented course is a creeping dose increase to achieve the same effect - precisely the path into dependence.
• Rebound insomnia: after discontinuation, sleep can temporarily be worse than before the first dose. This effect is regularly misread as “the sleep problem is back” and drives resumption. It is part of the withdrawal reaction, not the baseline state.
• Withdrawal symptoms: after prolonged use, anxiety, agitation, tremor, sweating, palpitations and in severe cases seizures are documented. Abrupt discontinuation after weeks of daily use is dangerous - tapering belongs in medical hands.
• Complex sleep behaviors (FDA Boxed Warning): sleepwalking, eating, phoning and driving while asleep with no subsequent memory. The FDA review captured 66 serious cases including 20 deaths, among them carbon monoxide poisoning, drowning, hypothermia, traffic collisions and suicides. These events also occurred after a first dose and at normal doses. A single such episode is treated as a contraindication to any further use.
• Combination with alcohol or opioids: potentially fatal. The respiratory depressant effects add up and alcohol amplifies sedation on top. The same applies to benzodiazepines, gabapentinoids, sedating antihistamines and GHB. There is no safe amount and no safe interval within the same night.
• Next-day driving ability: in meta-analyses of real driving tests, driving performance the morning after an evening 7.5mg dose was significantly impaired, more so after nighttime dosing. The impairment is regularly underestimated subjectively.
• Anterograde amnesia: memory gaps for the period after dosing are documented dose-dependently and are the reason complex sleep behaviors stay hidden from the affected person.
• Falls and fractures: cohort studies document a dose-dependent increase in fracture risk, particularly in older users. Getting up at night under residual sedation is the typical mechanism.
• Bitter metallic taste: the characteristic and most common adverse effect of zopiclone, occasionally persisting for hours. Harmless, but a reliable identifying feature of the substance.
• CYP3A4 interactions: inhibitors such as ketoconazole, erythromycin, clarithromycin or ritonavir clearly raise levels and sedation. Rifampicin lowers them.

This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.

Studies

• Zopiclone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy as an Hypnotic - Drugs 1986, Goa and Heel: foundational review of pharmacology and pharmacokinetics, documenting the roughly 5-hour half-life and the absence of long-acting metabolites.
• A Comparative Assessment of the Risks and Benefits of Zopiclone: A Review of 15 Years’ Clinical Experience - Drug Safety 1999, Hajak: review of 15 years of clinical use, efficacy of 7.5mg versus benzodiazepine hypnotics and the explicit cap of no more than 4 weeks of use.
• Hypnotics and Driving Safety: Meta-Analyses of Randomized Controlled Trials Applying the on-the-Road Driving Test - Current Drug Safety 2006, Verster et al: meta-analysis of standardized driving tests showing significant impairment of driving performance by zopiclone 7.5mg the morning after evening dosing and stronger impairment after nighttime dosing.
• Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death - Pharmacoepidemiology and Drug Safety 2020, Harbourt et al: FDA review of 66 cases of complex sleep behaviors with serious injuries and 20 deaths, which prompted the Boxed Warning for the Z-drug class.
• Are Seniors Dependent on Benzodiazepines? A National Clinical Survey of Substance Use Disorder - Clinical Pharmacology & Therapeutics 2020, Victorri-Vigneau et al: 45 percent of more than 1000 long-term users of benzodiazepines or Z-drugs met the formal DSM dependence criteria.